Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639662/
https://www.ncbi.nlm.nih.gov/pubmed/23634291
http://dx.doi.org/10.1002/cam4.71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639662/
https://www.ncbi.nlm.nih.gov/pubmed/23634291
http://dx.doi.org/10.1002/cam4.71

Ejemplares similares